Full Text | PDF

Share on facebook Share on tweeters Share on linkedin Share on googleplus

Int J Med Sci 2016; 13(6):418-423. doi:10.7150/ijms.15519 This issue Cite

Research Paper

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan

Tatsuo Kanda✉, Shin Yasui, Masato Nakamura, Eiichiro Suzuki, Makoto Arai, Yuki Haga, Reina Sasaki, Shuang Wu, Shingo Nakamoto, Fumio Imazeki, Osamu Yokosuka

Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

✉ Corresponding author: Tatsuo Kanda, M.D., Ph.D., Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. Tel.: +81-43-226-2086; Fax: +81-43-226 More

Citation:
Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci 2016; 13(6):418-423. doi:10.7150/ijms.15519. https://www.medsci.org/v13p0418.htm
Other styles

File import instruction

Abstract

Background. All-oral combination of direct-acting antivirals could lead to higher sustained virologic response (SVR) in hepatitis C virus (HCV)-infected patients. In the present study, we examined the efficacy and safety of the dual oral treatment with HCV nonstructural protein (NS) 5A inhibitor daclatasvir (DCV) plus HCV NS3/4A inhibitor asunaprevir (ASV) for 24 weeks in real-world HCV genotype 1-infected Japanese individuals.

Methods. After screening for HCV NS5A resistance-associated variants (RAVs) by PCR invader assay, a total of 54 Japanese patients infected with HCV genotype 1 treated with DCV plus ASV were retrospectively analyzed. SVR12 was used for evaluation of the virologic response.

Results. Of the total 54 patients, 46 patients (85.2%) were treated with DCV plus ASV for 24 weeks and achieved SVR12. The other 8 patients (14.8%) discontinued this treatment before 24 weeks due to adverse events. Of these 8 patients, 5 and 3 patients did and did not achieve SVR12, respectively. Finally, 51 of 54 (94.4%) patients achieved SVR12.

Conclusion. Treatment with DCV and ASV after screening for HCV NS5A RAVs by PCR invader assay is effective and safe in the treatment of real-world HCV genotype 1-infected patients in Japan.

Keywords: Asunaprevir, Daclatasvir, HCV NS5A, Interferon-free, Resistance-associated variants

Citation styles

APA
Kanda, T., Yasui, S., Nakamura, M., Suzuki, E., Arai, M., Haga, Y., Sasaki, R., Wu, S., Nakamoto, S., Imazeki, F., Yokosuka, O. (2016). Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. International Journal of Medical Sciences, 13(6), 418-423. https://doi.org/10.7150/ijms.15519.

ACS
Kanda, T.; Yasui, S.; Nakamura, M.; Suzuki, E.; Arai, M.; Haga, Y.; Sasaki, R.; Wu, S.; Nakamoto, S.; Imazeki, F.; Yokosuka, O. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int. J. Med. Sci. 2016, 13 (6), 418-423. DOI: 10.7150/ijms.15519.

NLM
Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci 2016; 13(6):418-423. doi:10.7150/ijms.15519. https://www.medsci.org/v13p0418.htm

CSE
Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O. 2016. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 13(6):418-423.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2025 Ivyspring International Publisher. Terms of use